+

PE20180046A1 - Anticuerpos terapeuticos y sus usos - Google Patents

Anticuerpos terapeuticos y sus usos

Info

Publication number
PE20180046A1
PE20180046A1 PE2017002104A PE2017002104A PE20180046A1 PE 20180046 A1 PE20180046 A1 PE 20180046A1 PE 2017002104 A PE2017002104 A PE 2017002104A PE 2017002104 A PE2017002104 A PE 2017002104A PE 20180046 A1 PE20180046 A1 PE 20180046A1
Authority
PE
Peru
Prior art keywords
seq
sequence seq
amino acid
acid sequence
antigen
Prior art date
Application number
PE2017002104A
Other languages
English (en)
Inventor
Tracy Chia Chien Kuo
Riggers Javier Fernando Chaparro
Wei Chen
Amy Shaw Ru Chen
Edward Derrick Pascua
Blarcom Thomas John Van
Leila Marie Boustany
Weihsien Ho
Yik Andy Yeung
Pavel Strop
Arvind Rajpal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55661497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE20180046A1 publication Critical patent/PE20180046A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a un anticuerpo aislado, o un antigeno que se une a un fragmento del mismo, que se une especificamente un antigeno de maduracion de celulas B (BCMA), en donde el anticuerpo comprende: (a.) una region variable de cadena pesada (VH) que comprende: (i) una region determinante de la complementariedad uno (CDR1) que comprende la secuencia de aminoacidos SEQ ID NO: 301, SEQ ID NO: 302,o SEC ID NO: 303; (ii) una CDR2 de VH que comprende la secuencia SEQ ID NO:305,o SEQ ID NO: 306; y (iii) una CDR3 de VH que comprende la secuencia SEQ ID NO: 307, SEQ ID NO: 308; (b.) una region variable de cadena ligera (VL) que comprende: (i) una CDR1 de VL que comprende la secuencia de aminoacidos SEQ ID NO: 309, (ii) una CDR2 de VL que comprende la secuencia SEQ ID NO: 310, Y (iii) una CDR3 de VL que comprende la secuencia de aminoacidos SEQ ID NO: 311, O SEQ ID NO: 312. Se relaciona aun mas con anticuerpos heteromultimericos que se unen especificamente a una Agrupacion de Diferenciacion 3 (CD3) y un antigeno de celula de tumor, (por ejemplo, anticuerpos biespecificos que se unen especificamente a CD3 y BCMA). Tambien se refiere a una composicion farmaceutica, un polinucleotido aislado, un vector y una celula huesped. Dicho anticuerpo bioespecifico es util como medicamento para el tratamiento de un cancer como el mieloma multiple, neoplasia maligno de celulas plasmaticas, entre otras.
PE2017002104A 2015-04-13 2016-03-30 Anticuerpos terapeuticos y sus usos PE20180046A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562146504P 2015-04-13 2015-04-13
US201562146843P 2015-04-13 2015-04-13
US201662301582P 2016-02-29 2016-02-29

Publications (1)

Publication Number Publication Date
PE20180046A1 true PE20180046A1 (es) 2018-01-15

Family

ID=55661497

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2022001051A PE20221262A1 (es) 2015-04-13 2016-03-30 Anticuerpos terapeuticos y sus usos
PE2022001050A PE20221580A1 (es) 2015-04-13 2016-03-30 Anticuerpos terapeuticos y sus usos
PE2017002104A PE20180046A1 (es) 2015-04-13 2016-03-30 Anticuerpos terapeuticos y sus usos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2022001051A PE20221262A1 (es) 2015-04-13 2016-03-30 Anticuerpos terapeuticos y sus usos
PE2022001050A PE20221580A1 (es) 2015-04-13 2016-03-30 Anticuerpos terapeuticos y sus usos

Country Status (30)

Country Link
US (6) US9969809B2 (es)
EP (3) EP3988117B1 (es)
JP (3) JP6913025B2 (es)
KR (3) KR102110557B1 (es)
CN (4) CN114874331B (es)
AU (3) AU2016248946C1 (es)
BR (1) BR112017019785B1 (es)
CA (4) CA3219684A1 (es)
CO (1) CO2017010495A2 (es)
DK (2) DK3988117T3 (es)
ES (2) ES3012402T3 (es)
FI (2) FI3988117T3 (es)
FR (1) FR24C1023I1 (es)
HK (1) HK1255385A1 (es)
HR (1) HRP20241757T1 (es)
HU (3) HUE057285T2 (es)
IL (4) IL310723A (es)
MX (3) MX2017013297A (es)
MY (1) MY196625A (es)
PE (3) PE20221262A1 (es)
PH (3) PH12023550223A1 (es)
PL (2) PL3283106T3 (es)
PT (2) PT3988117T (es)
RU (1) RU2722381C2 (es)
SA (1) SA517390140B1 (es)
SG (3) SG10201912819XA (es)
SI (2) SI3988117T1 (es)
TW (3) TWI703159B (es)
WO (1) WO2016166629A1 (es)
ZA (1) ZA201807153B (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
MX2018009700A (es) 2016-02-17 2019-01-24 Seattle Genetics Inc Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
PE20190120A1 (es) 2016-04-01 2019-01-17 Kite Pharma Inc Moleculas de union a bcma y metodos de uso de las mismas
LT3436030T (lt) 2016-04-01 2022-12-12 Kite Pharma, Inc. Chimeriniai receptoriai ir jų panaudojimo būdai
SG10201912489QA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3630841A1 (en) 2017-06-02 2020-04-08 Pfizer Inc. Antibodies specific for flt3 and their uses
CA3063598A1 (en) * 2017-06-14 2018-12-20 Dana-Farber Cancer Institute, Inc. B-cell maturation antigen (bcma)-directed nanoparticles
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
TWI815815B (zh) 2017-08-01 2023-09-21 美商麥迪紐有限責任公司 Bcma單株抗體-藥物結合物
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019053612A1 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
CN111108125A (zh) * 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CN111094353A (zh) * 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
KR102403046B1 (ko) * 2017-09-29 2022-05-30 재단법인 목암생명과학연구소 Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
TWI732176B (zh) 2018-02-01 2021-07-01 大陸商信達生物製藥（蘇州）有限公司 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
KR102768098B1 (ko) 2018-02-01 2025-02-17 화이자 인코포레이티드 Cd70에 특이적인 항체 및 이의 용도
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
CA3092037A1 (en) * 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
KR102665277B1 (ko) * 2018-02-27 2024-05-13 화이자 인코포레이티드 항체 정제
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3774901A1 (en) 2018-03-26 2021-02-17 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
PE20210127A1 (es) 2018-05-23 2021-01-19 Pfizer Anticuerpos especificos para cd3 y sus usos
CA3101050A1 (en) 2018-05-23 2019-11-28 Celgene Corporation Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
JP7057843B2 (ja) 2018-05-23 2022-04-20 ファイザー・インク ＧＵＣＹ２ｃに特異的な抗体及びその使用
SG11202010579XA (en) 2018-06-01 2020-12-30 Novartis Ag Binding molecules against bcma and uses thereof
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
KR102597053B1 (ko) * 2018-06-26 2023-11-02 에이비엘바이오 주식회사 항-bcma 항체 및 그 용도
WO2020006312A1 (en) * 2018-06-28 2020-01-02 Dana-Farber Cancer Institute, Inc. Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CN112437671B (zh) 2018-07-19 2025-02-25 瑞泽恩制药公司 具有bcma特异性的嵌合抗原受体及其用途
JP7515459B2 (ja) * 2018-08-08 2024-07-12 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂｃｍａ、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびに使用法
MX2021002393A (es) 2018-08-31 2021-07-15 Novartis Ag Metodos de preparacion de celulas que expresan receptores de antigenos quimericos.
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
TW202029980A (zh) * 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
BR112021010279A2 (pt) * 2018-12-01 2021-08-24 Allogene Therapeutics, Inc. Receptores de antígeno quimérico que alvejam antígeno de maturação de células b e métodos de uso dos mesmos
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
AU2019410073B2 (en) * 2018-12-21 2024-08-01 F. Hoffmann-La Roche Ag Tumor-targeted agonistic CD28 antigen binding molecules
KR20210134339A (ko) 2019-02-25 2021-11-09 노파르티스 아게 바이러스 전달을 위한 메조다공성 실리카 입자 조성물
AU2020228367A1 (en) * 2019-02-26 2021-10-14 Vivasor, Inc. Antigen binding proteins that bind BCMA
JP7633937B2 (ja) 2019-03-01 2025-02-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
BR112021018627A2 (pt) 2019-03-21 2021-11-23 Regeneron Pharma Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
WO2020261093A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
KR20220068984A (ko) * 2019-07-30 2022-05-26 상하이 한서 바이오메디컬 컴퍼니 리미티드 항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
EP4004045A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
EP4003526A2 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
BR112022002236A2 (pt) * 2019-08-06 2022-05-03 Glaxosmithkline Ip Dev Ltd Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
ES2987783T3 (es) 2019-11-11 2024-11-18 Amgen Res Munich Gmbh Régimen de dosificación para agentes anti-BCMA
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
JP2023505218A (ja) * 2019-12-06 2023-02-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof
WO2021121250A1 (zh) * 2019-12-17 2021-06-24 深圳市菲鹏生物治疗股份有限公司 Bcma结合抗体及其用途
EP4076465B1 (en) 2019-12-18 2023-11-15 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
KR20220012314A (ko) * 2020-01-03 2022-02-03 살루브리스 (청두) 바이오테크 코., 리미티드 Bcma에 결합하는 항체 및 그의 용도
CN111234020B (zh) * 2020-01-23 2020-10-23 和铂医药(苏州)有限公司 一种bcma结合蛋白及其制备方法和应用
MX2022010340A (es) * 2020-02-24 2022-09-19 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas.
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
AU2021228708A1 (en) 2020-02-27 2022-09-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP4114852A1 (en) * 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
CN115279781B (zh) * 2020-03-26 2025-05-09 上海翰森生物医药科技有限公司 抗体药物偶联物及其医药用途
BR112022021884A2 (pt) 2020-05-06 2022-12-20 Dragonfly Therapeutics Inc Proteínas que se ligam a nkg2d, cd16 e clec12a
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
KR20230009450A (ko) * 2020-05-11 2023-01-17 얀센 바이오테크 인코포레이티드 다발성 골수종을 치료하기 위한 방법
KR20230008197A (ko) 2020-05-13 2023-01-13 화이자 인코포레이티드 암을 치료하기 위한 방법, 요법 및 용도
CA3184645A1 (en) * 2020-06-05 2021-12-09 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
KR20230058427A (ko) 2020-08-21 2023-05-03 노파르티스 아게 Car 발현 세포의 생체내 생성을 위한 조성물 및 방법
EP4204092A1 (en) 2020-08-25 2023-07-05 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting hiv and methods of use
EP4211167A1 (en) 2020-09-14 2023-07-19 Pfizer Inc. Methods, therapies and uses for treating cancer
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
EP4538292A2 (en) 2021-01-28 2025-04-16 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2022177676A1 (en) * 2021-02-16 2022-08-25 City Of Hope Anti-domain iv egfr antibodies and uses thereof
CN117597359A (zh) 2021-04-08 2024-02-23 马伦戈治疗公司 与tcr结合的多功能分子及其用途
CN113358546A (zh) * 2021-04-21 2021-09-07 贵州安康医学检验中心有限公司 一种自身免疫性周围神经病相关抗体的联合检测方法
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
KR20240004659A (ko) 2021-04-30 2024-01-11 셀진 코포레이션 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
US20240344030A1 (en) * 2021-07-28 2024-10-17 Cartesian Therapeutics, Inc. Multiprotein-engineered cells secreting a multispecific antibody
CA3228064A1 (en) 2021-08-12 2023-02-16 Shanghai Jmt-Bio Technology Co., Ltd. Gpc3-targeted antibody interferon .alpha. fusion protein and use thereof
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
WO2023028612A2 (en) 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
CN118043356A (zh) * 2021-09-27 2024-05-14 Xencor股份有限公司 B细胞成熟抗原（bcma）结合结构域组合物
CR20240170A (es) * 2021-10-29 2024-05-24 Lilly Co Eli Compuestos y métodos dirigidos a la interleucina-34
CA3237357A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
KR20240141208A (ko) 2022-03-03 2024-09-25 화이자 인코포레이티드 다중특이적 항체 및 그의 용도
CN119546329A (zh) 2022-04-11 2025-02-28 瑞泽恩制药公司 用于通用肿瘤细胞杀伤的组合物和方法
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
EP4540278A1 (en) 2022-06-17 2025-04-23 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
CR20240556A (es) 2022-07-05 2025-01-29 Pfizer Compuestos de pirido[4,3-d]pirimidina
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024121777A1 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2024196816A2 (en) * 2023-03-17 2024-09-26 Twist Bioscience Corporation Variant nucleic acid libraries for bcma
WO2024209339A1 (en) 2023-04-05 2024-10-10 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
US20240398982A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
TW202504929A (zh) 2023-06-22 2025-02-01 美商建南德克公司 用於癌症治療之方法及組成物
WO2025032521A1 (en) 2023-08-10 2025-02-13 Pfizer Inc. Methods, therapies and uses for treating cancer
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
JP3250802B2 (ja) 1989-03-21 2002-01-28 バイカル・インコーポレイテッド 脊椎動物における外因性ポリヌクレオチド配列の発現
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
CA2066053C (en) 1989-08-18 2001-12-11 Harry E. Gruber Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994023697A1 (en) 1993-04-22 1994-10-27 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
AU690583B2 (en) 1993-09-15 1998-04-30 Novartis Vaccines And Diagnostics, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU3734900A (en) 1999-03-09 2000-09-28 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
HU230583B1 (hu) 1999-08-17 2017-02-28 Biogen Idec Ma Inc. BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2003221256A1 (en) 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
JP4524181B2 (ja) * 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US9034324B2 (en) * 2009-03-10 2015-05-19 Biogen Idec Ma Inc. Anti-BCMA antibodies
EP2496686A1 (en) 2009-11-04 2012-09-12 DSM IP Assets B.V. Talaromyces transformants
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP6105477B2 (ja) 2010-11-05 2017-03-29 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
US20130101599A1 (en) * 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
SG194176A1 (en) * 2011-05-27 2013-12-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HUE035463T2 (hu) 2011-11-17 2018-05-02 Pfizer Citotoxikus peptidek és ezek antitest-hatóanyag konjugátumai
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
UA119227C2 (uk) 2012-04-20 2019-05-27 Аптево Рісьорч Енд Девелопмент Ллс Поліпептид, що зв'язується з cd3
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
CA2919583C (en) 2013-07-31 2018-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
HUE050156T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
IL248257B2 (en) 2014-04-30 2024-08-01 Max Delbruck Centrum Fur Molekulare Medizin In Der Helmholtz Gemeinschaft Humanized antibodies against cd269 (bcma)
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen

Also Published As

Publication number Publication date
EP3988117B1 (en) 2024-11-27
KR102405104B1 (ko) 2022-06-07
ZA201807153B (en) 2022-08-31
IL290488B2 (en) 2024-07-01
JP6913025B2 (ja) 2021-08-04
MX2022001830A (es) 2022-03-17
CN114874331B (zh) 2025-01-07
US10040860B2 (en) 2018-08-07
FR24C1023I1 (fr) 2024-07-26
SI3283106T1 (sl) 2022-04-29
HUE069499T2 (hu) 2025-03-28
SA517390140B1 (ar) 2021-11-24
IL290496A (en) 2022-04-01
TWI787645B (zh) 2022-12-21
TWI703157B (zh) 2020-09-01
SG10201912823PA (en) 2020-02-27
FIC20240014I1 (fi) 2024-05-21
KR20170131699A (ko) 2017-11-29
TW201811833A (zh) 2018-04-01
PE20221580A1 (es) 2022-10-06
HRP20241757T1 (hr) 2025-02-28
US20160297885A1 (en) 2016-10-13
TWI703159B (zh) 2020-09-01
WO2016166629A1 (en) 2016-10-20
AU2016248946B2 (en) 2022-03-10
US20180171018A1 (en) 2018-06-21
US11155630B2 (en) 2021-10-26
CO2017010495A2 (es) 2018-01-05
PH12023550222A1 (en) 2024-03-11
HUS2400014I1 (hu) 2024-06-28
MX2022001831A (es) 2022-03-17
PL3283106T3 (pl) 2022-05-02
DK3283106T3 (da) 2022-01-10
AU2016248946A1 (en) 2017-09-21
FI3988117T3 (fi) 2025-01-27
PT3988117T (pt) 2025-01-23
IL290488B1 (en) 2024-03-01
BR112017019785B1 (pt) 2022-11-16
PT3283106T (pt) 2022-02-02
JP7641323B2 (ja) 2025-03-06
RU2722381C2 (ru) 2020-05-29
IL310723A (en) 2024-04-01
US20210054087A1 (en) 2021-02-25
US9969809B2 (en) 2018-05-15
CA3219684A1 (en) 2016-10-13
KR102110557B1 (ko) 2020-05-15
MY196625A (en) 2023-04-23
TW201706311A (zh) 2017-02-16
CN119708245A (zh) 2025-03-28
CA3219680A1 (en) 2016-10-13
RU2017133826A3 (es) 2019-05-13
US20180298108A1 (en) 2018-10-18
KR20200053642A (ko) 2020-05-18
CA2925329A1 (en) 2016-10-13
PH12017501732A1 (en) 2018-04-02
KR102405099B1 (ko) 2022-06-07
CN108136002B (zh) 2022-05-31
DK3988117T3 (da) 2025-01-20
RU2017133826A (ru) 2019-05-13
CN114773476A (zh) 2022-07-22
CA3219665A1 (en) 2016-10-13
SI3988117T1 (sl) 2025-03-31
CN108136002A (zh) 2018-06-08
TW202115120A (zh) 2021-04-16
US20210188991A1 (en) 2021-06-24
ES2905315T3 (es) 2022-04-07
EP4234581A2 (en) 2023-08-30
JP2021169486A (ja) 2021-10-28
BR112017019785A2 (pt) 2018-05-22
AU2022203620A1 (en) 2022-06-16
AU2016248946C1 (en) 2024-10-17
SG11201707192XA (en) 2017-10-30
HUE057285T2 (hu) 2022-04-28
IL254219A0 (en) 2017-10-31
SG10201912819XA (en) 2020-02-27
MX2017013297A (es) 2018-06-19
IL290488A (en) 2022-04-01
PE20221262A1 (es) 2022-08-16
EP3283106B1 (en) 2021-12-22
HK1255385A1 (zh) 2019-08-16
JP2023109898A (ja) 2023-08-08
ES3012402T3 (en) 2025-04-09
PL3988117T3 (pl) 2025-03-10
US11814435B2 (en) 2023-11-14
US10793635B2 (en) 2020-10-06
AU2022203601A1 (en) 2022-06-16
EP4234581A3 (en) 2023-10-04
JP2018516068A (ja) 2018-06-21
EP3283106A1 (en) 2018-02-21
PH12023550223A1 (en) 2024-03-11
CN114874331A (zh) 2022-08-09
IL254219B (en) 2022-03-01
KR20200053641A (ko) 2020-05-18
US20240018252A1 (en) 2024-01-18
CA2925329C (en) 2024-01-02
EP3988117A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
PE20190737A1 (es) Anticuerpos anti-cd27
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
PE20190976A1 (es) Anticuerpos de union a cd3
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20180795A1 (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
CO2018004094A2 (es) Polipéptidos de unión a cd3
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
PE20180484A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
PE20170263A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
CO2017005738A2 (es) Anticuerpos anti-pd-1
MX2018012468A (es) Construcciones de union a antigeno multiespecificas dirigidas a agentes inmunoterapeuticos.
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
PE20141017A1 (es) Anticuerpos del cea
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载